Lopinavir/r (meltrex) filed in South Africa

Abbott announced on 4 April 2006 that it has filed for registration of meltrex lopinavir/r (non refrigerated) formulation in South Africa. The company also announced that this would be price-matched to the current formulation ($500 per patient, per year in Africa and the Least Developed Countries (LDCs).

Source: Abbott press release

Links to other websites are current at date of posting but not maintained.